Archived NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer
This activity will help clinicians identify the best treatment options for their patients with bladder cancer.
Category
- Bladder Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Cost $0.00
Recorded Presentation from the NCCN Pharmacy Updates: Maintenance Strategies in the Management of Acute Myeloid Leukemia
Maintenance therapy is an aspect of acute myeloid leukemia (AML) management that currently demonstrates strong promise in efforts to prolong survivability and improve overall survival. Given the forthcoming evidence in this area, it is highly important for health care professionals responsible for the care of patients with AML to be aware of both new treatment standards and emerging research in maintenance therapy options.
Category
- Acute Myelogenous Leukemia
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Cost $0.00
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.
Category
- Acute Lymphoblastic Leukemia
- Hematologic Malignancies
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Cost $0.00
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies.
Category
- Acute Lymphoblastic Leukemia
- Hematologic Malignancies
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Cost $0.00
Managing Earlier Integration of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia
While blinatumomab has been utilized in the setting of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) for years, emerging data has shown promising clinical efficacy with its use as post-remission therapy.
Category
- Acute Lymphoblastic Leukemia
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Review of Oral Targeted Therapies in Acute Myeloid Leukemia
In recent years, there has been an increased emphasis on molecular and genetic alterations in the classification system of acute myeloid leukemia, and, with this, an increase in the development of targeted therapies.
Category
- Acute Myelogenous Leukemia
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00
Myelodysplastic Syndromes: Treatment Updates and Emerging Data
The management of myelodysplastic syndromes (MDS) is complicated by the generally advanced age of the patients. The major clinical problems are morbidities caused by cytopenias and the potential for MDS to progress to acute myeloid leukemia.
Category
- Myelodysplastic Syndromes
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Cost $0.00
Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.
Category
- Multiple Myeloma
Format
- Recorded Webcast
Credits
- 2.25 AAPA Category 1 CME credit
- 2.25 ACPE contact hours
- 2.25 AMA PRA Category 1 Credit™
- 2.25 ANCC contact hours
- 2.25 Participation
Cost $0.00
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia
As additional, more effective, and novel therapies are added to the repertoire of cancer therapy, there are increasing numbers of cancer survivors, and these survivors are living for longer periods of time from diagnosis.
Category
- Acute Lymphoblastic Leukemia
- Multiple Myeloma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Cost $0.00
Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma?
Polatuzumab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) has emerged as a new first-line therapy option for patients with advanced stage diffuse large B-cell lymphomas (DLBCL).
Category
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Cost $0.00